CXCR3 and breast carcinoma: Our results confirm recent findings by Xu et al, who demonstrated the efficacy of the CART/STING-L combination in a unilateral model of locally advanced breast cancer.38 These authors have shown that the subcutaneous injection of STING-L at a site remote from the tumor leads to an enhanced expression of CXCL9/10 within the TME and CXCR3 on tumor-infiltrating T cells.39 CXCL9/10 chemokines recruit CXCR3-expressing effector T cells39 and the CXCL-9–10/CXCR3 axis prompted by STING-L-derived signals may explain the increased numbers of CART and endogenous T cells within the tumors.